Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Esther N. Dekker

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3040-6736; OpenAlex author ID A5082808892. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2023: 1 paper · 2024: 2 papers · 2025: 7 papers · 2026: 6 papers

Papers 16

  1. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. Co-author DOI 10.1093/jnci/djag024↗
  2. Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consorti… Co-author DOI 10.1093/jnci/djag033↗
  3. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. First author DOI 10.1097/sla.0000000000007025↗
  4. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  5. Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancreatic Surgery Consorti… Co-author DOI 10.1245/s10434-026-20620-5↗
  6. ASO Visual Abstract: Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancre… Co-author DOI 10.1245/s10434-026-20742-w↗
  7. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. First author DOI 10.1016/j.ejca.2025.116099↗
  8. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  9. Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical… Co-author DOI 10.1093/bjs/znaf011↗
  10. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  11. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  12. The Landmark Series: Neoadjuvant Therapy for Resectable Pancreatic Cancer. First author DOI 10.1245/s10434-025-17736-5↗
  13. ASO Author Reflections: The Landmark Series-Neoadjuvant Therapy for Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17835-3↗
  14. Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1093/bjs/znae244↗
  15. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. Co-author DOI 10.1200/jco.23.01311↗
  16. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. Co-author DOI 10.1186/s12885-023-11141-5↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bas Groot Koerkamp · 12 shared papers, 2023–2026 · strength 2.45
  2. Marc G. Besselink · 12 shared papers, 2023–2026 · strength 2.45
  3. Ching-Wei David Tzeng · 8 shared papers, 2024–2026 · strength 2.31
  4. Matthew H. G. Katz · 7 shared papers, 2024–2026 · strength 1.77
  5. Eva M M Verkolf · 8 shared papers, 2023–2026 · strength 1.52
  6. Roeland F. de Wilde · 7 shared papers, 2024–2026 · strength 1.42
  7. Amer H. Zureikat · 6 shared papers, 2024–2026 · strength 1.41
  8. Alice Chia-Chi Wei · 6 shared papers, 2024–2026 · strength 1.41
  9. Eileen Mary O'Reilly · 6 shared papers, 2024–2026 · strength 1.32
  10. Quisette P. Janssen · 6 shared papers, 2024–2026 · strength 1.15
  11. Alessandro Paniccia · 5 shared papers, 2024–2026 · strength 1.15
  12. Jacob L. van Dam · 6 shared papers, 2023–2026 · strength 1.08
  13. Marjolein Y.V. Homs · 6 shared papers, 2023–2026 · strength 1.05
  14. Casper H.J. van Eijck · 6 shared papers, 2023–2026 · strength 1.00
  15. Ignace H. J. T. de Hingh · 5 shared papers, 2023–2026 · strength 0.87
  16. Bert A. Bonsing · 5 shared papers, 2023–2026 · strength 0.87
  17. Laura R. Prakash · 4 shared papers, 2024–2026 · strength 0.87
  18. Johanna W. Wilmink · 5 shared papers, 2023–2026 · strength 0.84
  19. Geertjan van Tienhoven · 4 shared papers, 2023–2026 · strength 0.67
  20. Marion B.M. van der Kolk · 4 shared papers, 2023–2026 · strength 0.67
  21. Hjalmar C. van Santvoort · 4 shared papers, 2023–2026 · strength 0.67
  22. Thomas F. Stoop · 3 shared papers, 2024–2026 · strength 0.55
  23. Gijs A. Patijn · 3 shared papers, 2025–2026 · strength 0.54
  24. Jun Okui · 2 shared papers, 2026 · strength 0.54
  25. Naruhiko Ikoma · 2 shared papers, 2026 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.